Actual Nurtec ODT Patient
Actual Nurtec ODT Patient
CGRP: calcitonin gene-related peptide
Can be taken up
to once daily as
needed. No water
Can be co‑administered
with oral contraceptives
Studied in patients
in people with stable
or risk factors.
*The safety of treating more than 15 migraines in a 30-day period has not been established.1
Instruct patients to only
remove Nurtec ODT
from the blister pack
immediately before use1
No titration needed1
Patients can place
Nurtec ODT on or under
their tongue and it
In clinical trials, some
pain relief and returned
to normal function in
just 60 minutes with
Nurtec ODT has
a Tmax of 1.5 hours1,2
In a multi-center, double-blind, randomized, placebo-controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), the co-primary endpoints were freedom from pain and the absence of the most bothersome symptom (MBS) 2 hours post dose.1,2,4
*37% (n=246/669) patients experienced pain relief vs 31% (n=213/682) on placebo (p<0.05).
22% (n=149/669) patients experienced freedom from functional disability vs 16% (n=108/682) on placebo (p=0.0025).2,4
References: 1. Nurtec ODT [prescribing information]. New Haven, CT: Biohaven Pharmaceuticals, Inc. 2. Croop R et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. 3. Abay FB and Ugurlu T. Orally Disintegrating Tablets: A Short Review. J Pharm Drug Devel. 2015;3(3):303-311. 4. Data on File 001. Biohaven Pharmaceuticals, Inc.
Savings & Support
Contraindications: Hypersensitivity to Nurtec ODT or any of its components.
Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.
Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.
Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P‑gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.
Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.
Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.
Please click here for full Prescribing Information.